DelveInsight’s “Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Sarcoidosis, historical and forecasted epidemiology as well as the Sarcoidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Sarcoidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sarcoidosis Market Forecast

Some of the key facts of the Sarcoidosis Market Report: 

• The Sarcoidosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In April 2024, Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company focused on developing treatments for rare inflammatory and autoimmune diseases, have announced the successful completion of enrollment in their Phase 2 study evaluating namilumab for chronic pulmonary sarcoidosis (RESOLVE-Lung). Sarcoidosis, an immune-mediated inflammatory disease affecting multiple organs, is estimated to impact approximately 200,000 people in the U.S. and over 1 million people globally, with around 90% of cases involving the lungs. Namilumab, a potent anti-GM-CSF monoclonal antibody, is designed for convenient once-monthly subcutaneous administration and has the potential to become the first disease-modifying therapy for sarcoidosis. RESOLVE-Lung, a randomized, double-blind, placebo-controlled Phase 2 study, aims to enroll at least 100 pulmonary sarcoidosis patients whose condition remains poorly controlled despite current treatment options.

• In March 2024, Molecure has administered the first dose to a subject in the UK for its Phase II KITE clinical trial of OATD-01, a potential treatment for active pulmonary sarcoidosis. The first dose of OATD-01, a chitotriosidase 1 (CHIT1) inhibitor or placebo, was given at the Royal Infirmary in Edinburgh, marking a significant milestone in the study of this multi-organ disease.

• DelveInsight’s analysis revealed that the total number of existing cases of Sarcoidosis in the 7MM was reported to be 251,866 in 2022 and is projected to increase steadily with a notable compound annual growth rate (CAGR) over the study period.

• The United States reported the highest number of diagnosed prevalent cases of Sarcoidosis, estimated to be approximately 157,233 in 2022, with expectations of a substantial increase indicated by a significant compound annual growth rate (CAGR).

• In 2022, sarcoidosis affected 42% of males and 58% of females across the 7MM. Gender-specific instances in the EU4 and the UK totaled 35,297 for males and 50,450 for females in 2022, with projections indicating a rise within the forecast period (2023−2032).

• Key Sarcoidosis Companies: Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, aTyr Pharma, and others

• Key Sarcoidosis Therapies: Abrocitinib, Inhaled Treprostinil, XTMAB-16, Efzofitimod, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others

• A variety of emerging treatments for Sarcoidosis, such as KRP-R120 (efzofitimod), CMK389, OATD-01, XTMAB-16, among others, are under development. There remains a significant gap in effective therapies to address this disease. However, ongoing research and trials hold promise for potentially transforming the market landscape.

• The Sarcoidosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sarcoidosis pipeline products will significantly revolutionize the Sarcoidosis market dynamics.

Sarcoidosis Overview

Sarcoidosis is a rare inflammatory disease that can affect multiple organs in the body, most commonly the lungs and lymph nodes. In sarcoidosis, abnormal masses or nodules called granulomas form in certain organs of the body. These granulomas can alter the normal structure and function of the affected organs.

Get a Free sample for the Sarcoidosis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/sarcoidosis-market

Sarcoidosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sarcoidosis Epidemiology Segmentation:

The Sarcoidosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Sarcoidosis

• Prevalent Cases of Sarcoidosis by severity

• Gender-specific Prevalence of Sarcoidosis

• Diagnosed Cases of Episodic and Chronic Sarcoidosis

Download the report to understand which factors are driving Sarcoidosis epidemiology trends @ Sarcoidosis Epidemiology Forecast

Sarcoidosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sarcoidosis market or expected to get launched during the study period. The analysis covers Sarcoidosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sarcoidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sarcoidosis Therapies and Key Companies

• Abrocitinib: Pfizer

• Inhaled Treprostinil: United Therapeutics

• XTMAB-16: Xentria, Inc.

• Efzofitimod: aTyr Pharma, Inc./Kyorin Pharmaceutical Co., Ltd

• CMK389: Novartis

• Namilumab: Kinevant Sciences GmbH

• FP-020: Foresee Pharmaceuticals

• LAM001: AI Therapeutics

• OATD-01: Molecure

Discover more about therapies set to grab major Sarcoidosis market share @ Sarcoidosis Treatment Landscape

Sarcoidosis Market Drivers

• Strategic alliances between the Pharmaceutical companies and universities, extensive research undertaking and funding are some of the important factors that are fueling the Sarcoidosis Market.

Sarcoidosis Market Barriers

• However, side-effects associated with the treatment of Sarcoidosis, lack of awareness among people in developing countries and other factors are creating obstacles in the Sarcoidosis Market growth.

Scope of the Sarcoidosis Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Sarcoidosis Companies: Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, aTyr Pharma, and others

• Key Sarcoidosis Therapies: Abrocitinib, Inhaled Treprostinil, XTMAB-16, Efzofitimod, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others

• Sarcoidosis Therapeutic Assessment: Sarcoidosis current marketed and Sarcoidosis emerging therapies

• Sarcoidosis Market Dynamics: Sarcoidosis market drivers and Sarcoidosis market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Sarcoidosis Unmet Needs, KOL’s views, Analyst’s views, Sarcoidosis Market Access and Reimbursement 

To know more about Sarcoidosis companies working in the treatment market, visit @ Sarcoidosis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Sarcoidosis Market Report Introduction

2. Executive Summary for Sarcoidosis

3. SWOT analysis of Sarcoidosis

4. Sarcoidosis Patient Share (%) Overview at a Glance

5. Sarcoidosis Market Overview at a Glance

6. Sarcoidosis Disease Background and Overview

7. Sarcoidosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Sarcoidosis 

9. Sarcoidosis Current Treatment and Medical Practices

10. Sarcoidosis Unmet Needs

11. Sarcoidosis Emerging Therapies

12. Sarcoidosis Market Outlook

13. Country-Wise Sarcoidosis Market Analysis (2019–2032)

14. Sarcoidosis Market Access and Reimbursement of Therapies

15. Sarcoidosis Market Drivers

16. Sarcoidosis Market Barriers

17.  Sarcoidosis Appendix

18. Sarcoidosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/